docetaxel + modafinil

Docetaxel + modafinil is a combination of two pharmaceutical agents used together in clinical research settings, primarily to address chemotherapy-induced fatigue. Docetaxel is a taxoid antineoplastic agent that promotes the assembly and stabilization of microtubules, thereby inhibiting their normal dynamic reorganization essential for cell division, leading to apoptosis in cancer cells. It is widely used in the treatment of various cancers, including breast and prostate cancer[3][6]. Modafinil is a central nervous system stimulant approved for sleep disorders such as narcolepsy; it acts as a wakefulness-promoting agent with psychoactive effects similar to other stimulants[8]. In clinical trials, modafinil has been investigated for its potential to reduce fatigue associated with docetaxel-based chemotherapy regimens. While some studies suggest modest improvements in fatigue symptoms when both drugs are administered concurrently, results have not shown statistically significant differences compared to placebo[1][2][5].